Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). Landos completed a $60 million Series B financing round in August of 2019. The company has completed Phase 1 clinical testing, initiated Phase 2 clinical testing of BT-11 for ulcerative colitis and plans a Phase 2 trial in Crohn’s disease in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases in preclinical and IND-enabling stages, several of which will advance to clinical stage in 2020.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):